Oncology Learning Network

Oncology Learning Network® is an online resource for the latest updates in oncology practice. Official digital home for @OLNGreatDebates and @LLMCongress.

[Oncology Learning Network @OncLearnNetwork]

New data from #ESMO2026: Results from DASL-HiCaP show that adding #darolutamide to ADT and radiotherapy improved metastasis-free survival in patients with very high-risk localized or recurrent prostate cancer.

Learn more: https://t.co/sen3Win2zT

[Oncology Learning Network @OncLearnNetwork]

🚨 Results from DeLLphi-305: #Tarlatamab plus #durvalumab significantly improved survival in the first-line maintenance setting for patients with extensive-stage #SCLC, supporting a potential new treatment standard.

Learn more: https://t.co/PCN3okb96g

#ESM02026 #MedTwitter

[Oncology Learning Network @OncLearnNetwork]

As presented at #ESMO2026, perioperative #durvalumab plus neoadjuvant enfortumab vedotin significantly improved survival in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based therapy.

Learn more: https://t.co/Nf0cr8cVME

[Oncology Learning Network @OncLearnNetwork]

New data from #ESMO2026: Personalized mRNA therapy with #intismeran plus #pembrolizumab significantly improved recurrence-free and distant metastasis-free survival in high-risk resected #melanoma, supporting a promising adjuvant strategy.

Learn more: https://t.co/3RO8Oftei4

[Oncology Learning Network @OncLearnNetwork]

Watch the final installment of this APP/MD conversation covering the biggest highlights in GI cancers from the ASCO 2026 Annual Meeting.

🔗https://t.co/l67pQl3DFi

#ASCO2026AnnualMeeting #GICancer

[Oncology Learning Network @OncLearnNetwork]

Based on results from #KEYNOTE158, the @FDA has approved #pembrolizumab and #pembrolizumab plus berahyaluronidase alfa for previously untreated patients with TMB-high unresectable or metastatic solid tumors.

Learn more: https://t.co/f6mGyPk7F8

[Oncology Learning Network @OncLearnNetwork]

Stephanie Berg, DO, discusses evolving frontline treatment strategies for metastatic clear cell #RCC, highlighting individualized treatment selection and emerging second-line options. Learn more: https://t.co/wArZhiinij

[Oncology Learning Network @OncLearnNetwork]

Advanced practice providers (APPs) can play a major role for patients being treated for multiple myeloma. In this video interview, Donna Catamero, ANP-BC, OCN, CCRC, shares the basics you should know!

👉https://t.co/lylu4hoKra

#MultipleMyeloma #OncologyAPP

[Oncology Learning Network @OncLearnNetwork]

Sequential #cytarabine induction followed by #azacitidine plus #lenalidomide showed clinical activity in very-high-risk #MDS, suggesting a potential treatment approach in resource-limited settings. Learn more: https://t.co/2epVuEnG18

[Oncology Learning Network @OncLearnNetwork]

Want to catch up on the latest research presented at this year's JADPRO Live conference?

Check in with the JADPRO Live newsroom, here: https://t.co/06FWrNELxt

#JADPROLive2026 #OncologyAPP

[Oncology Learning Network @OncLearnNetwork]

Catherine Diefenbach, MD, discusses evolving frontline treatment options for classical #Hodgkin lymphoma, highlighting the importance of balancing efficacy, toxicity, and financial burden as #immunotherapy-based regimens expand. Learn more: https://t.co/HmE6g3GVCu

[Oncology Learning Network @OncLearnNetwork]

In this APP Institute case presentation, Mary Steinbach, NP, discusses extramedullary progression after CAR-T therapy in a patient with high-risk multiple myeloma.

Learn more: https://t.co/u0s4xsxQzt

#multiplemyeloma #howitreat

[Oncology Learning Network @OncLearnNetwork]

🚨: @FDA grants accelerated approval to #dostarlimab (Jemperli) for stage II/III MSI-H/dMMR locally advanced rectal cancer based on #AZUR1 results, offering a potential organ-preserving treatment approach. Learn more: https://t.co/1iKP69L6m2

[Oncology Learning Network @OncLearnNetwork]

In this video interview, Madeline Merrill, AGNP-BC, MSN, discusses care delivery innovations highlighted at the 2026 ASCO Annual Meeting and their implications for oncology APPs.

Learn more: https://t.co/blhvxNQxOA

#ASCO2026 #cancercaredelivery

[Oncology Learning Network @OncLearnNetwork]

In this video interview, Sally Fang, MSN, RN, FNP-BC, tackles the question of what it means to be an APP in the evolving field of breast medical oncology. Watch now on the APP Institute!

🔗https://t.co/k8tuFLcyHQ

#BreastCancer #OncologyAPP

[Oncology Learning Network @OncLearnNetwork]

🚨: The @FDA has expanded approval of nogapendekin alfa inbakicept plus BCG to include patients with BCG-unresponsive non-muscle-invasive bladder cancer with high-grade papillary-only tumors.

Learn more: https://t.co/yaSWdWVK67

[Oncology Learning Network @OncLearnNetwork]

Marlise Luskin, MD, discusses the evolving role of #MRD assessment in #ALL, highlighting its potential to guide treatment decisions, refine risk stratification, and reduce unnecessary chemotherapy exposure. Learn more: https://t.co/3KDuoyktDM

[Oncology Learning Network @OncLearnNetwork]

The conversation continues off the stage 🎥

We sat down with @SoniSmithMD and @NGhoshMD to dig deeper into their perspectives and the clinical implications of today’s discussions. Stay tuned!

#LLMcongress #medtwitter #onctwitter

[Oncology Learning Network @OncLearnNetwork]

In part 2 of their video interview, Dr. Tanios Bekaii-Saab and Jonathan Catrona discuss some of the top highlights in GI cancer out of this year's ASCO Annual Meeting.

Watch Now: https://t.co/6JErmiI9E2

#ASCO2026 #GICancer

[WCM Englander Institute for Precision Medicine @WCMEnglanderIPM]

Thanks @OncLearnNetwork for "Targeted Radionuclide Therapy Moves Earlier Across the Cancer Treatment Continuum," by @WCMEnglanderIPM's @DrScottTagawa on targeted radionuclide therapy and theranostics in #oncology.

https://t.co/XES0VtPi3K